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Abstract
We previously showed that broadly neutralizing anti-HIV-1 antibody 2G12 (human IgG1) naturally forms dimers that are
more potent than monomeric 2G12 in in vitro neutralization of various strains of HIV-1. In this study, we have investigated
the protective effects of monomeric versus dimeric 2G12 against HIV-1 infection in vivo using a humanized mouse model.
Our results showed that passively transferred, purified 2G12 dimer is more potent than 2G12 monomer at preventing CD4 T
cell loss and suppressing the increase of viral load following HIV-1 infection of humanized mice. Using humanized mice
bearing IgG ‘‘backpack’’ tumors that provided 2G12 antibodies continuously, we found that a sustained dimer
concentration of 5–25 mg/ml during the course of infection provides effective protection against HIV-1. Importantly,
2G12 dimer at this concentration does not favor mutations of the HIV-1 envelope that would cause the virus to completely
escape 2G12 neutralization. We have therefore identified dimeric 2G12 as a potent prophylactic reagent against HIV-1 in
vivo, which could be used as part of an antibody cocktail to prevent HIV-1 infection.
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Introduction
Human efficacy trials of vaccine candidates designed to elicit
antibody-based immunity against HIV-1 have mostly failed [1,2],
raising questions as to whether such an approach to HIV-1
vaccination is at all feasible. A recent human vaccine trial in
Thailand [3], however, provided a promising signal of efficacy.While
there is no direct evidence of which component of the vaccine was
effective, it could be antibody-based immunity. In the trial, 98.6% of
vaccinated individuals produced ‘‘binding antibodies’’ against HIV-1
envelope protein gp120 although no broadly neutralizing antibodies.
The possibility that antibody-mediated protection was effective has
reenergized the search for effective anti-HIV-1 antibodies.
Existing broadly neutralizing anti-HIV-1 antibodies are valu-
able starting points for generating protection against HIV-1.
Several broadly neutralizing antibodies have been proposed as the
basis for designing protective mechanisms against HIV-1 in recent
years [4,5]. Among them, 2G12 is unique, because it recognizes a
constellation of carbohydrates on gp120 [6,7,8,9] and has an
unusual structure that involves a domain swap between the two
heavy chains [8]. 2G12 is most effective at neutralizing clade B
strains of HIV-1 [10].
A series of studies have described the in vivo protective effects of
2G12 against simian/HIV-1 in macaques [11,12,13] and against
HIV-1 in humans [14,15,16,17]. Interestingly, in the studies where
2G12 was combined with other broadly neutralizing antibodies
such as 4E10 and 2F5 [16,17], 2G12 provided the dominant
protective effect against HIV-1. The relatively long in vivo half-life
of 2G12 can partially explain this phenomenon [18]. However,
albeit protective, 2G12 also selected HIV-1 escape mutants in vivo
[16,19]; therefore, it is important to identify a new reagent or
method to minimize the rate of appearance of such escape mutants.
We have previously shown that 2G12 IgG1 can form natural
dimers that are 50-80–fold more potent than monomeric 2G12
IgG1 in in vitro neutralization of various strains of HIV-1 [20].
2G12 monomer, in common with typical IgGs, contains two
antigen-binding Fabs and one Fc region, but the heavy chain
regions of the Fabs are domain-swapped to create a single (Fab)2
unit [8]. 2G12 dimer contains four Fabs and two Fcs, which form a
structure, presumably through inter-molecular domain swapping,
that does not interconvert with 2G12 monomer [20]. The present
study was designed to investigate the in vivo potency of dimeric
2G12 in controlling HIV-1 infection in a humanized mouse model.
We show that dimeric 2G12 is effective at providing protection
against HIV-1 without selecting viral mutants that would
completely escape 2G12 neutralization, suggesting that the 2G12
dimer is a suitable prophylactic reagent for use against HIV-1.
Results
Dimeric 2G12 is more potent than monomeric 2G12 in
vivo after passive transfer
The dimeric form of the monoclonal antibody 2G12 possesses
increased in vitro neutralization potency compared to the
monomeric form [20]. It is unknown, however, whether dimeric
2G12 would have a long enough half-life to be more effective than
the 2G12 monomer at preventing HIV-1 infection in vivo. To
address this question, we prepared separate stocks of purified
2G12 monomer and dimer and passively transferred 0.5 mg/
mouse of 2G12 monomer or dimer into Rag22/2cc
2/2 mice
reconstituted with human immune cells (Supporting Figure S1A).
We then challenged the mice intravenously (i.v.) with the CCR5-
tropic strain of HIV-1, JR-CSF, at a dose of 400 ng of p24.
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Using an ELISA targeting a Myc tag fused to the light chain of
the purified antibodies, we found that the concentration of 2G12
monomer declined quickly in the mouse plasma whereas the 2G12
dimer was relatively stable (Figure 1A). The elimination (b phase)
half-lives of the purified human IgGs in the humanized mouse
plasma were estimated as 3.560.9 days for the 2G12 dimer and
0.960.2 days for the 2G12 monomer. The 2G12 dimer prevented
CD4 T cell loss in the peripheral blood following HIV-1 infection,
whereas the 2G12 monomer did not provide protection (Figure 1B).
In addition, the 2G12 dimer moderately suppressed the increase of
viral load in the blood (Figure 1C), causing an overall reduction of
97.5% in viral load compared to the control that lacked antibody
(Figure 1D). The 2G12 monomer, on the other hand, did not
suppress the increase of viral load following HIV-1 infection
(Figure 1C). We also analyzed the percentages of T cells and the
numbers of p24+ cells in the spleen, thymus, and mesenteric lymph
node. As shown in Figure 1E, we found that without 2G12, HIV-1
almost completely depleted CD4+ cells in the spleen. The
percentage of splenic CD8+ cells also decreased, presumably
because they rely on CD4+ T helper cells for proliferation and
survival [21]. Between the two forms of 2G12, the monomer had a
minimal effect at preventing the loss of CD4+ and CD8+ splenocytes
following HIV-1 infection, whereas the 2G12 dimer was able to
rescue nearly half of the CD4+ cells and most of CD8+ cells in the
spleen (Figure 1E). A similar effect was observed in the mesenteric
lymph node (Figure S1B) but not in the thymus (Figure S1C),
presumably because a CCR5-tropic virus was used and there are
few CCR5+ T cells in the thymus [22]. Immunohistochemical
analysis using an antibody against HIV-1 p24 confirmed that the
2G12 dimer was effective at limiting HIV-1 infection in both the
spleen and the mesenteric lymph node (Figure 1F). HIV-1 p24+ cells
were hardly found in the thymus (data not shown).
These results demonstrated increased protection against HIV-1
of purified 2G12 dimer compared to 2G12 monomer when the
antibodies were administered to humanized mice prior to HIV-1
challenge.
2G12 dimer provided continuously at a low level is
sufficient for protection against HIV-1
To investigate whether the higher potency of 2G12 dimer
compared to the monomer resulted only from its longer in vivo
half-life, we modified the conventional humanized mice [23,24] to
carry antibody-expressing cells as backpacks [25] that produced
antibodies continuously throughout the course of HIV-1 infection
(Figure 2). This strategy avoided the dramatic fluctuation of
antibody concentrations that usually occur when antibodies were
administered through multiple administrations [16,17]. The
antibody-expressing cells were injected subcutaneously (s.c.) and
formed localized backpacks whose size could be controlled by the
administration of ganciclovir, a prodrug that killed backpacked
cells co-expressing herpes simplex virus thymidine kinase (TK)
along with the antibody [26]. Because the backpack size positively
correlated with the concentration of 2G12 in the blood (Figure
S2A), we could control the backpack size to limit the antibody
concentration within a reasonably small range.
We made mice with backpacks that expressed wild-type 2G12
(named ‘‘2G12 BP’’) and those with backpacks expressing D2, a
mutant of 2G12 that is expressed with an increased dimer/monomer
ratio [20] (named ‘‘D2 BP’’). We previously reported that wild-type
2G12 cells produce 78% monomer and 22% dimer whereas the D2
clone produced 60% monomer and 40% dimer; and that the
monomers and dimers produced by wild-type 2G12 or D2 2G12
exhibited no significant differences in biophysical and neutralization
characteristics [20]. Since the 2G12 monomer and dimer share the
same heavy and light chains, an ELISA would not distinguish
between the two forms, making it difficult to directly measure the
dimer:monomer ratios in the backpacked mice. Size exclusion
chromatography, which could be normally used to determine relative
levels of monomer and dimer, would require several milliliters of
mouse blood for each sample collection, which was not feasible.
Instead, we calculated the monomer:dimer ratios based on the
production ratios of monomer versus dimer in the two cell lines (3.5: 1
for 2G12 BP and 1.5: 1 for D2 BP) and their individual half-lives in
the humanized mice (see Materials andMethods for details). We then
used the ratios to estimate the concentrations of 2G12 dimer and
2G12monomer in the blood samples (Table 1; concentrations of total
2G12 and 2G12 dimer are shown; the concentration of 2G12
monomer can be obtained by subtracting the dimer concentration
from the concentration of total 2G12).
The D2 BP provided an estimated 3-5-fold more dimer than the
2G12 BP during the first 3 weeks of HIV-1 infection (Table 1;
p,0.02 for weeks 0, 1, 2 and 3). The concentrations of 2G12
monomer were not significantly different between the D2 BP and
2G12 BP groups at each time point (p.0.05) although the
combined 2G12 concentrations were higher in the D2 BP group
due to significantly greater dimer concentrations. Analysis of the
peripheral blood lymphocytes showed that 2G12 BP barely had
any protective effect on CD4 T cells compared to the control that
lacked antibody (Figure 3A, weeks 1, 2 and 4). In contrast, D2 BP
effectively protected CD4 T cells from being cleared by HIV-1
after one week of infection (Figure 3A, week 1; p,0.05). D2 BP
also appeared to offer some protection for CD4 T cells 2 and 4
weeks after HIV-1 inoculation although the effect was not
statistically significant. Analysis of HIV-1 copy numbers in the
mouse plasma showed that D2 BP moderately suppressed the viral
load at each time point (Figure 3B) and significantly suppressed the
overall viral load (Figure S2B; p,0.01), suggesting that D2 BP is
potent at preventing viral entry and/or eliminating HIV-1 from
the circulation. The mice with D2 BP also had significantly lower
numbers of p24+ cells in the mesenteric lymph node than mice
carrying 2G12 BP (Figure 3C), although neither backpack
significantly protected the spleen from HIV-1 infection
(Figure 3D for the percentage of CD4 T cells and Figure S2C
for the number of p24+ cells).
Since D2 BP did not completely prevent HIV-1 infection of
humanized mice (i.e., HIV-1 viral load was still detectable in the
mouse plasma), we asked if increasing the concentration of 2G12
Author Summary
Most successful vaccines function by eliciting antibodies
that bind to the surface of pathogens of interest from the
host immunologic repertoire. This should also be the case
for an HIV-1 vaccine, but broadly neutralizing anti-HIV-1
antibodies have proven hard to elicit with any reagent.
Thus, methods to directly administer broadly neutralizing
anti-HIV-1 antibodies, such as passive transfusion, become
appealing. It is therefore important to find out which
antibodies, or antibody cocktails, would provide effective
protection against HIV-1 before administering them. Here,
we show that the dimeric fraction of 2G12, a unique
monoclonal anti-HIV-1 antibody that dimerizes naturally,
provides better protection against HIV-1 than its mono-
meric fraction. As an added bonus, although HIV-1 can
evolve to completely escape antibody control, the 2G12
dimer does not favor such evolution. Our study suggests
that the 2G12 dimer may be a suitable reagent for direct
administration to protect people from HIV-1 infection.
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to over 100 mg/ml [11,12,13] would provide better protection
against HIV-1. Thus, we included a group of mice (named ‘‘BP ’’)
that carried large wild-type 2G12 backpacks as a means to
maintain both 2G12 monomer and 2G12 dimer at high
concentrations in the peripheral blood (Table 1). Our results
showed that the large backpacks prevented HIV-1-induced CD4 T
cell loss in the peripheral blood (Figure 3A, weeks 1, 2, and 4),
suppressed HIV-1 viral load in the mouse plasma (Figure 3B and
Figure S2B), decreased the number of p24+ cells in the mesenteric
lymph node (Figure 3C), and minimized the decrease of CD4 T
cell percentage in the spleen (Figure 3D). However, the virus was
still detectable in the periphery (Figure 3B). In fact, the overall
viral load in BP mice was similar to that of D2 BP mice (Figure
S2B), suggesting that the concentration of 2G12 dimer required to
neutralize HIV-1 in vivo might be as low as 5–25 mg/ml (Table 1,
dimer concentrations in the D2 BP group from week 0 to week 4),
a level that led to over 70% neutralization of the virus (Figure 3B,
comparing D2 BP to the control group lacking antibody).
Providing 10-fold more of the 2G12 dimer could potentially
prevent CD4 T cell loss in the peripheral blood for a longer period
of time (Figure 3A), but it would not prevent HIV-1 entry or
further decrease HIV-1 viral load in the plasma (Figure 3B and
Figure S2B) or mesenteric lymph node (Figure 3C).
These results showed that a continuous supply of dimeric 2G12
at 5–25 mg/ml during the course of HIV-1 infection is effective at
protecting humanized mice against HIV-1 infection.
Figure 1. Protection against HIV-1 infection in humanized mice by passively transferred 2G12 dimer. Humanized mice were injected
(i.v.) with 0.5 mg of purified 2G12 monomer (n = 6) or 2G12 dimer (n = 5) at 4 months of age and challenged by HIV-1JR-CSF (i.v.; 400 ng of p24) one
day after passive transfer. (A) Concentrations of 2G12 in the mouse plasma. 2G12 was measured by Myc-specific ELISA and data are shown as average
6 s.e.m. All data shown from now on are average 6 s.e.m. unless a bar graph is shown, where the data are presented as average + s.e.m. (B) The
ratios of human CD4:CD8 in the peripheral blood. CD4 and CD8 cell populations were measured weekly by flow cytometry. The ratios of CD4:CD8,
after normalization to week-0 values (set as 1), were plotted. Mice with no antibody but HIV-1 challenge (n = 7) and mice with neither antibody nor
HIV-1 (n = 6) were used as controls. The CD4:CD8 ratio in this humanized mouse model increased with the age of the mice as seen in the ‘‘No HIV; No
antibody’’ control. Therefore, all mice involved in this study were age-matched. One-way analysis of variance (ANOVA) with Tukey’s multiple
comparison posttest showed that the group with 2G12 dimer was not different from the No HIV-1 control (p.0.05); however, it had significantly
higher CD4:CD8 ratios than the group with 2G12 monomer (p,0.05). All data points in each treatment group, regardless of time, were included in the
ANOVA. (C) Viral load in the mouse plasma. Viral RNA was extracted from mouse plasma and the viral load was measured. The detection limit of the
assay was 20,000 HIV-1 copies/ml of mouse plasma. The differences were not statistically significant. (D) Total viral load from week 0 to week 4. Area
under the curve (AUC) of the viral load during week 0-4 was calculated and plotted. The group with 2G12 dimer had significantly lower viral load than
the other two groups based on individual Mann-Whitney tests (p=0.0303 between 2G12 dimer and No antibody; p= 0.0159 between the 2G12 dimer
and 2G12 monomer). (E) Percentages of human CD4 and CD8 T cells in the spleen after 4 weeks. Plots shown were pre-gated on CD3 T cells.
(F) Immunohistochemical analysis of HIV-1 p24 in the spleen and mesenteric lymph node after 4 weeks. The images were taken using an Olympus
BX51 microscope with 4006magnification (Scale bar, 25 mm).
doi:10.1371/journal.ppat.1001225.g001
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Dimeric 2G12 at a low level does not favor HIV-1
envelope mutations at residue N295
Since 2G12 is known to induce HIV-1 escape mutants [16,19],
we extracted viral RNA from the week-4 plasma of 3 or 4
representative mice per experimental group, cloned the JR-CSF
envelope gene from viral cDNA, and sequenced at least 10 clones
per mouse sample. Some viral clones had spontaneous mutations
at residue N339 regardless of the presence of 2G12 and might
represent a background in the inoculum (Table 2 and Figure 4A).
In addition, both 2G12 BP and D2 BP selected mutations at
Figure 2. Generation of humanized mice with IgG ‘‘backpack’’ tumors. Rag22/2cc
2/2mice were intrahepatically (i.h.) injected with 0.1-0.26106
human CD34+ hematopoietic stem and progenitor cells at 1 day of age. The humanizedmicewere screened for CD45+ human cells at 6 weeks of age, andmice
with good reconstitution were selected for the following procedures. First, to achieve a sustained level of anti-HIV-1 neutralizing antibodies (NAb) in mice, we
delivered the antibodies through subcutaneous (s.c.) injection of a cell line on the right side of the lower back when the mice were 3-months-old. The cell line,
293T/TK/NAb, formed controllable packs on the lower back of the mice. The backpack size was closely monitored biweekly and the drug ganciclovir was
injected (i.p.) after HIV-1 challenge and when the backpacks exceeded the size limit of 1.5 cm2. The concentrations of 2G12 produced in the blood were
monitored by ELISA. Second, to establish HIV-1 infection in these mice, the JR-CSF strain of the virus was injected intravenously (i.v.) at a dose of 400 ng p24
when the backpacked mice were approximately 4-month-old. The infected mice were monitored weekly for the percentages of T cell populations, the HIV-1
viral load, and the concentrations of 2G12 in the blood. They were sacrificed 4 weeks after HIV-1 inoculation and the blood and tissues were analyzed.
doi:10.1371/journal.ppat.1001225.g002
Table 1. Concentrations of total 2G12 and 2G12 dimer (average 6 s.e.m.) in backpacked mice.
2G12 BP (mg/ml) D2 BP (mg/ml) BP (mg/ml)
Weeks after
HIV-1 injection Total Dimer Total Dimer Total Dimer
0 1.7 6 0.9 0.9 6 0.5 7.1 6 3.2b 5.1 6 2.4d 110.4 6 14.9 58.2 6 7.9
1 3.2 6 1.4 1.7 6 0.7 8.6 6 2.2b 6.2 6 1.6d 224.8 6 46.6 118.5 6 24.6
2 5.7 6 1.9 3.0 6 1.0 12.9 6 2.5 9.3 6 1.8d 448.9 6 105.0 236.7 6 55.4
3 7.2 6 2.3 3.8 6 1.2 17.7 6 2.3b 12.8 6 1.6d 293.0 6 88.0 154.4 6 46.4
4 31.5 6 4.9 16.6 6 2.6 34.4 6 1.6 24.8 6 1.2 208.3 6 21.5 109.8 6 11.4
AUCa 37.1 6 6.8 17.2 6 3.8 61.3 6 6.0c 44.2 6 4.3e 1139.06 158.2 506.1 6 87.0
Plasma concentrations of 2G12 (Total) were measured by ELISA. 2G12 dimer and 2G12 monomer concentrations were then calculated as described in the text and
Materials and Methods. Concentrations of total 2G12 and 2G12 dimer are shown; the concentration of 2G12 monomer for each condition is obtained by subtracting the
dimer concentration from the concentration of total 2G12. BP, backpacks. BP , large backpacks that yield high concentrations of 2G12. Ganciclovir was injected to
control the size of the backpacks below 1.5 cm2.
aAUC: area under the curve from week 0 to week 4.
bSignificant difference in total 2G12 concentration between D2 BP and 2G12 BP. Mann-Whitney tests showed that the p values for week 0, 1, 3 were 0.0256, 0.0228,
0.0221, respectively.
cSignificant difference in AUC of total 2G12 between D2 BP and 2G12 BP (Mann-Whitney test; p=0.0411).
dSignificant difference in 2G12 dimer concentration between D2 BP and 2G12 BP. Mann-Whitney tests showed that the p values for week 0, 1, 2, 3 were 0.0198, 0.0084,
0.0197, 0.014, respectively.
eSignificant difference in AUC of 2G12 dimer between D2 BP and 2G12 BP (Mann-Whitney test; p=0.0047).
doi:10.1371/journal.ppat.1001225.t001
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residue N386. Surprisingly, we observed an unusually high
percentage of mutations at residue N295 when the 2G12
concentration was kept at 100 mg/ml or higher (Table 2 and
Figure 4A; BP ). This residue, along with N332 that was not
significantly mutated in this study, have been suggested as the key
anchors of glycans that form the 2G12 epitope [7]. To assess the
sensitivity of mouse-derived viruses to 2G12 neutralization, we
performed in vitro neutralization assays using pseudoviruses made
with JR-CSF envelope genes that we obtained from mouse plasma
samples. Both the input virus (the pseudovirus that shared the
same JR-CSF envelope as the inoculum) and the virus with mouse-
derived envelope that did not encounter any neutralizing antibody
in vivo (HIV-1 only; No mutation) were effectively neutralized by
2G12 monomer and 2G12 dimer in vitro (Figure 4B and 4C); but
the half maximal inhibitory concentration (IC50) of 2G12 dimer
was 33-fold less than the IC50 of the monomer, suggesting that the
2G12 dimer was more potent at neutralizing the JR-CSF strain of
HIV-1 than the 2G12 monomer. More importantly, we found that
the viral envelope from a BP mouse with the mutation N295S
caused the pseudovirus to completely escape the neutralization
effect of both the 2G12 monomer (Figure 4B) and the 2G12 dimer
(Figure 4C). In contrast, a virus variant with a mutation at residue
386 was partially neutralized by the 2G12 monomer and 2G12
dimer. This suggests that, unlike the .100 mg/ml condition
(provided by BP ), the presence of 2G12 dimer at 5–25 mg/ml
(provided by D2 BP) did not select for complete HIV-1 escape
mutants.
Therefore, our results showed that although constant adminis-
tration of 2G12 at high concentrations was potent at protecting
humanized mice from HIV-1 infection in vivo, it resulted in
Figure 3. Protection against HIV-1 infection in humanized mice by a sustained low level of dimeric 2G12. Backpacked mice were
generated as described in Figure 2. Backpacks expressing wild-type 2G12 were named ‘‘2G12 BP’’ (n = 8) whereas the ones expressing D2 mutant
were named ‘‘D2 BP’’ (n = 7). Another group of mice (n = 7) were made to carry large wild-type 2G12 backpacks (‘‘BP ’’) that generated .100 mg/ml
of 2G12 monomer plus dimer in the blood before HIV-1 inoculation. The concentrations of total 2G12 and 2G12 dimer are shown in Table 1. (A) Fold
differences of %CD4 T cells in the peripheral blood from week 0 to week 1, week 2, or week 4. CD4 T cells were measured weekly by flow cytometry.
One-way ANOVA with Tukey’s multiple comparison posttest showed that the group with D2 BP had a significantly higher percentage of CD4 T cells
than the ‘‘HIV-1; No Ab’’ control (n = 7) at week 1 (p,0.05). The BP group had significantly higher percentages of CD4 T cells than the ‘‘HIV-1; No Ab’’
group for week 1, week 2, and week 4 (p,0.05). (B) Viral load in the mouse plasma. The detection limit of the assay was 20,000 HIV-1 copies/ml of
mouse plasma. The differences were not statistically significant. The virus was not detectable in two different mice in the D2 BP group at week 1 and
week 4, respectively. One mouse in the BP group also had undetectable viral load at week 4. The D2 BP mice had an averaged 90% reduction in viral
load from the ‘‘HIV; No Ab’’ control at week 1 and 4. At week 2, the averaged reduction was 70%. (C) Number of p24+ cells in the mesenteric lymph
node (mLN). Four weeks after HIV-1 challenge, mLNs were harvested, fixed, and sectioned for immunohistochemical analysis of HIV-1 p24. The
numbers of p24+ cells were counted manually and presented as the number of cells per mm2 area of the specimen. One-way ANOVA with Tukey’s
multiple comparison posttest showed that both D2 BP and BP groups had significantly lower numbers of p24+ cells in mLN than the HIV-1 groups
with 2G12 BP or no antibody (p,0.05). (D) Percentage of CD4 T cells in CD3+ splenocytes. Mice were sacrificed after 4 weeks and human T cells in
their spleens were analyzed by flow cytometry. The groups were not significantly different.
doi:10.1371/journal.ppat.1001225.g003
Dimeric 2G12 as a Potent Protection against HIV-1
PLoS Pathogens | www.plospathogens.org 5 December 2010 | Volume 6 | Issue 12 | e1001225
HIV-1 envelope mutations that could completely escape 2G12
neutralization. However, at least over the time-course of our
experiments, a low level of 2G12 dimer did not specifically select
the same mutations, providing an additional benefit to its high
potency.
Discussion
In this study, we used a humanized mouse model to investigate
the in vivo potency of dimeric 2G12 in controlling HIV-1
infection. This mouse model supports human hematopoietic
development, provides human CD4 T cells as natural targets of
HIV-1 infection, and allows for possible selection of viral resistance
[27]. Using these mice, we first examined the stability and
protective effects of monomeric and dimeric forms of 2G12 in
HIV-1-challenged humanized mice by passively transferring
purified antibodies. We found that the 2G12 dimer had a longer
in vivo half-life and was more potent than the 2G12 monomer at
controlling HIV-1 infection in vivo. The elimination half-life of the
2G12 dimer was 3.5 days in humanized mice and comparable to
the reported elimination half-life (3.2 days) of human IgG1 in mice
[28]. This is shorter than the half-life of human IgG1 in humans
[18] but correlates with the difference in body weight between
mice and humans [29]. To investigate whether a continuous
supply of the 2G12 monomer would overcome its poor in vivo
efficacy, we next used a backpacking approach to provide the
antibody continuously. Using wild-type 2G12 as the backpacked
gene, we achieved a sustained level of 2G12 monomer and dimer
in the mouse plasma. However, constant delivery of 2G12
monomer plus a small amount of 2G12 dimer at a low level (1–
4 mg/ml dimer for the first 3 weeks and 16.6 mg/ml dimer after 4
weeks) did not protect the mice from HIV-1 infection. In contrast,
backpacks containing the D2 mutant, which produced increased
levels of 2G12 dimer (60% monomer, 40% dimer) provided
effective protection against HIV-1 by maintaining a 2G12 dimer
concentration of 5–25 mg/ml in the mouse plasma. Thus, our
results suggest that, administered either through a single injection
or continuously, dimeric 2G12 is a more potent prophylactic anti-
HIV-1 antibody than 2G12 monomer.
Several in vivo studies have estimated that concentrations of
2G12 of 100 mg/ml or higher exert a protective effect against
HIV-1 when the virus is given at a 50% tissue culture infective
dose (TCID50) of 500—5,000 [11,12,13]. In order to establish a
robust and consistent infection in humanized mice, we adminis-
tered HIV-1 intravenously at a dosage of 400 ng p24, or a
TCID50 of 400,000. Although sterilizing immunity was not
achieved in this study, we found that, even with high-dose HIV-1
challenge, 2G12 monomer and dimer at combined concentrations
of 100 mg/ml or higher could significantly reduce the severity of
HIV-1 infection in the humanized mice (Figure 3). More
importantly, the D2 BP that delivered 2G12 at a much lower
concentration exerted a similar protective effect against HIV-1. In
particular, D2 BP provided the 2G12 dimer at 5–25 mg/ml, which
was sufficient to prevent peripheral blood CD4 T cell loss
(Figure 3A) and suppress the increase of the viral load follow-
ing HIV-1 infection (Figure 3B and Figure S2B). Therefore,
2G12 dimer represents a promising prophylactic reagent against
HIV-1 in vivo because it neutralizes HIV-1 at a relatively low
concentration.
Having a low effective concentration is not the only advantage
of the 2G12 dimer as a protective reagent against HIV-1. 2G12 is
known to select HIV-1 escape mutants both in vitro [30,31] and in
vivo [16,30,31], with in vivo escape mutants detectable as early as
4 weeks after HIV-1 inoculation [16,30,31]. Here we analyzed the
diversity of HIV-1 viral RNA isolated from the mouse plasma,
focusing on regions of the JR-CSF envelope gene where 2G12
epitope-containing carbohydrates would attach [7,32]. We found
that while low levels of 2G12 dimer induced mutations at residue
N386, 2G12 at monomer plus dimer concentrations of .100 mg/
ml specifically selected mutations at another residue (Table 2).
This residue, N295, has been suggested to be one of the two
central players in the interaction between 2G12 and its
carbohydrate epitope [7]. A mutation at N295 would be more
likely to allow HIV-1 to escape 2G12 neutralization than
mutations at other sites such as N386 (Figure 4B and Figure 4C).
Thus, at least over the time-course of our experiments, dimeric
2G12 provided protection against HIV-1 without selecting for
complete HIV-1 escape mutants.
Table 2. Percentage of viral clones mutated at different Asp (N) sites in the JR-CSF envelope gene.
Experimental group Mouse # N295 N332 N339 N386 N392 N448 Any N
HIV-1; no antibody M40 0.0 0.0 14.3 0.0 0.0 0.0 14.3
HIV-1; no antibody M5 0.0 0.0 7.7 0.0 0.0 0.0 7.7
HIV-1; no antibody M127 0.0 0.0 31.3 0.0 0.0 0.0 31.3
HIV-1; no antibody M129 0.0 0.0 11.1 0.0 0.0 0.0 11.1
HIV-1; 2G12 BP M27 0.0 0.0 0.0 82.4 0.0 0.0 82.4
HIV-1; 2G12 BP M13 0.0 0.0 0.0 42.9 0.0 0.0 42.9
HIV-1; 2G12 BP M15 0.0 0.0 20.0 12.5 0.0 0.0 18.2
HIV-1; 2G12 BP M38 6.7 0.0 6.7 40.0 0.0 0.0 20.0
HIV-1; D2 BP M122 0.0 0.0 17.6 20.0 0.0 0.0 35.3
HIV-1; D2 BP M120 8.3 0.0 8.3 8.3 16.7 0.0 41.7
HIV-1; D2 BP M117 7.1 7.1 0.0 7.1 7.1 0.0 28.6
HIV-1; D2 BP M116 0.0 0.0 0.0 87.5 0.0 0.0 87.5
HIV-1; BP M159 66.7 0.0 0.0 0.0 0.0 0.0 66.7
HIV-1; BP M165 15.4 0.0 0.0 0.0 0.0 0.0 15.4
HIV-1; BP M167 23.5 0.0 11.8 11.8 58.8 11.8 82.4
doi:10.1371/journal.ppat.1001225.t002
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In summary, we found in the present study that dimeric 2G12,
or the D2 mutant that increases the production of dimeric 2G12,
might be potential prophylactic reagents against HIV-1. However,
more research is necessary to characterize the tissue distribution of
dimeric 2G12 and its in vivo antibody-dependent cellular
cytotoxicity activity. It is also important to assess the immunoge-
nicity of 2G12 in its dimeric form since it is twice the size of a
typical IgG. In addition, the pharmacokinetics of dimeric 2G12
should be carefully established in human studies, as the half-life of
the antibody in humans is likely to be different from that in
humanized mice. Furthermore, because the neutralization spec-
trum of 2G12 is not particular good when tested against a large
panel of HIV-1 isolates [10] and neutralizing antibodies have
demonstrated synergy when combined together [33], the 2G12
dimer may be more beneficial when used as part of an antibody
cocktail to protect people from HIV-1 infection.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and
Use Committee (IACUC) of California Institute of Technology
(Animal Assurance Number: A3426-01). All animal experiments
were conducted under IACUC protocols 1536-09G and 1547-
08G.
Figure 4. Sequence changes in HIV-1 envelopes and antibody escape. (A) Mouse-derived HIV-1 envelope sequences (regions of interest). Viral
RNAwas extracted frommouse plasma 4 weeks after HIV-1 challenge, reverse transcribed, and sequenced as described in Materials and Methods. The HIV-1
envelope sequences cloned frommice were aligned to the wild-type JRCSF envelope sequence. The percentages of viral clones with mutations are shown
in Table 2. Three sequences from two representative mice of each group are shown in this panel, with the mouse number shown in parentheses. The
sequence numbers are also shown next to the sequences. For better viewing, all relevant Asn codons (N295, N332, N339, N386, N392, N448) and their
adjacent Ser/Thr codons with mutations are shown in red and blue, respectively, except for the wild-type JRCSF sequence where the wild-type codons are
colored. The mutated nucleotides are also bolded and underlined. Some nucleotides other than those that form the carbohydrate anchors were also
mutated and they are in black color and underlined. (B) Antibody escape. Four representative envelope genes (labeled with ** in panel A) were subcloned
into an expression plasmid for the in vitro neutralization assay. The viral envelope from a D2 BP mouse had a single mutation of N386T. This mutation also
occurred in 2G12 BP mice. The viral envelope from a BP mouse had a mutation of N295S. The viral envelope from an HIV-1-only mouse contained no
mutations. The envelope of the virus injected to mice (the input virus) was used as the control. Pseudoviruses were made from these envelopes and in vitro
neutralization assay was performed. Neutralization of pseudoviruses by the 2G12monomer is shown in this panel. (C) Pseudoviruses weremade and in vitro
neutralization assay was performed as described in panel B. Neutralization of pseudoviruses by the 2G12 dimer is shown in this panel.
doi:10.1371/journal.ppat.1001225.g004
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Expression and purification of 2G12
The wild-type 2G12 heavy chain gene (IgG1) and a Myc-tagged
2G12 light chain gene were linked by an F2A sequence and
subcloned into a lentivector. The vector is a third-generation, self-
inactivating lentiviral vector backbone based on pHRST [34,35].
Briefly, the StuI fragment of pHRST containing a complete viral
genome was ligated into the pUC19 backbone to remove
exogenous flanking genomic sequences. PCR-cloning was em-
ployed to introduce restriction sites flanking the promoter and
transgene to facilitate subsequent cloning. Further modifications
were made to pHAGE6 to remove extraneous viral sequences with
no effect on virus function (A.B., to be published elsewhere).
Lentiviruses were then generated by transient transfection of
HEK-293T cells using the Trans-IT reagent (Mirus Bio; Madison,
WI) and used to create a 293T stable cell line that produced 2G12.
The 2G12-expressing, adherent stable cell line was adapted for
growth in suspension for large-scale production of 2G12 at the
Caltech Protein Expression Center. Cell culture supernatants were
collected and passed over protein A resin (Pierce Biotechnology;
Rockford, IL), and eluted using using pH 3.0 citrate buffer.
Protein A eluates were immediately neutralized and then subjected
to size exclusion chromatography in 20 mM Tris pH 8.0,
150 mM NaCl using a Superdex 200 16/60 (GE Healthcare).
Fractions corresponding to monomer and dimer were collected
and then separately passaged over a Superdex 200 10/30 column
(GE Healthcare) to remove contaminating amounts of monomer
or dimer from the separated purified species.
Humanized mice, passive transfer, and HIV-1 challenge
Frozen human cord blood CD34+ cells from single donors were
purchased from AllCells (Emeryville, CA) or Lonza (Basel,
Switzerland). One-day-old Rag22/2cc
2/2 pups were irradiated
and intrahepatically (i.h.) injected with 0.1-0.26106 human cord
blood CD34+ cells per pup. Mice were then screened for human
CD45+ cells at 6 weeks of age and those with good reconstitution
were chosen for the study (Figure S1A). For passive transfer
experiments, one single dose of 0.5 mg/mouse of purified 2G12
dimer or 2G12 monomer was injected retro-orbitally (i.v.) into 4-
month-old humanized mice 1 day before HIV-1 challenge. The
HIV-1 JR-CSF plasmid was obtained from NIH AIDS Research
and Reference Reagent Program and transiently transfected into
293T cells to produce infectious HIV-1 particles. The culture
medium containing HIV-1 was then harvested and titered using
the p24 ELISA kit from PerkinElmer (Waltham, MA). The virus
was injected (i.v.) at 400 ng p24/mouse. For non-HIV-1 mice,
conditioned medium was injected as the control. All mice involved
in this study were age-matched since the CD4:CD8 ratio naturally
increased with the age of these mice.
Generation of backpacked mice
Wild-type 2G12 and D2 mutant genes were cloned into
lentiviral vectors. Lentiviruses were then generated and used to
create stable cell lines that produced wild-type 2G12 and D2,
respectively. The parent cell line was a stable 293T cell line that
expressed herpes simplex virus thymidine kinase (TK), so the
progeny lines were named 293T/TK/2G12 and 293T/TK/D2
cell lines. When well-reconstituted humanized mice were 3-
month-old, 16106 of backpacked cells were injected (s.c.) on the
back of the mice at the lower right side. Backpack size (length6
width) was measured weekly and controlled by injection (i.p.) of
62.5 mg or 125 mg (depending on the backpack size) of ganciclovir
(Sigma; St. Louis, MO) per mouse after HIV-1 challenge and
when the backpack size reached 1.5 cm2.
Sample collection
Weekly blood samples were obtained retro-orbitally and the
plasma was immediately separated from blood cells and stored for
viral RNA extraction and Myc-specific ELISA (see below for
details). The peripheral blood mononuclear cells after antibody
staining were analyzed by the FACSCalibur (BD Biosciences; San
Jose, CA). Mice were sacrificed 4 weeks after HIV-1 challenge.
Blood, spleen, thymus, and mesenteric lymph node were collected
for flow cytometry analysis or fixation in formalin. The fixed
tissues were then send to University of California, Los Angeles for
immunohistochemical analysis.
Determination of 2G12 concentrations
Mouse plasma was diluted 1:10, 1:100, and 1:1000 in sample
diluent and heat-inactivated at 55uC for 1 h. Myc-tagged 2G12
was captured by anti-human IgG-Fc (Bethyl Laboratories;
Montgomery, TX) and detected by anti-Myc conjugated with
horseradish peroxidase (Bethyl Laboratories; Montgomery, TX).
The plates were read at 450 nm on a SpectroMax Reader
(Molecular Devices, Sunnyvale, CA) after the addition of the TMB
substrate and the stop solution. In passive transfer experiments, the
half-life of the elimination phase (b phase), which took place after
the redistribution phase, was determined using a one-phase
exponential decay model using data points from week 0 (24 h
after the injection of 2G12 monomer or dimer) to week 4. The
half-lives were estimated as 3.560.9 days for the 2G12 dimer and
0.960.2 days for the 2G12 monomer. In backpacking experiments
where both 2G12 monomer and dimer were present in the
plasma, we determined their individual concentrations by
calculating the monomer:dimer ratios as following:
LP
Lt
~b{aP
where P= protein (monomer or dimer), b= production rate; a=
degradation rate. Assuming that at the time of HIV-1 challenge (4
weeks after backpack injection), the monomer and dimer had
reached their individual steady state (i.e.
LP
Lt
~0),
b~aP [ P~ b
a
If the dimer had a production rate of b and a degradation rate of
a, then the monomer should have a production rate of 3.5b (78%
monomer versus 22% dimer produced from 2G12 backpacks) and
a degradation rate of 3.9a (dimer:monomer ratio of half-lives 3.5/
0.9 = 3.9) for 2G12 backpacks. Thus,
Pmonomer~
3:5b
3:9a
~0:9|
b
a
~0:9|Pdim er
i:e:,
Pmonomer
Pdim er
~0:9 2G12backpackð Þ
Therefore, the 2G12 monomer and dimer concentrations were
calculated as:
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Pdim er~
1
0:9z1
 
|Ptotal~0:53|Ptotal
and, Pmonomer~Ptotal{Pdim er
where Ptotal= total 2G12 concentration as measured by Myc-
specific ELISA. For D2 backpacks, since the dimer’s production
rate was 1.5b (60% monomer versus 40% dimer produced from
D2 backpacks) and the degradation rate stayed the same,
Pmonomer
Pdim er
~0:4 D2backpackð Þ
thus, Pdim er~
1
0:4z1
 
|Ptotal~0:71|Ptotal
In-house HIV-1 viral load assay
Viral RNA was extracted from mouse plasma using QIAamp
Viral RNA Mini Kit from Qiagen (Valencia, CA). The RNA
(200 ng) was reverse transcribed and quantified using the Taqman
RNA-to-CT One-Step Kit (Applied Biosystems; Foster City, CA)
and the Eppendorf Realplex real-time PCR system (Hauppauge,
NY). The primers were designed to anneal to the pol region of the
HIV-1 genome within the first intron, so that only unspliced viral
RNA could be detected. The primer sequences were: forward
primer, 59-CAA TGG CAG CAA TTT CAC CA-39; reversed
primer, 59-GAA TGC CAA ATT CCT GCT TGA-39. The probe
sequence was: 59-/56-FAM/CCC ACC AAC AGG CGG CCT
TAA CTG/36-TAMSp/-39. HIV-1 RNA standard was generated
using the Riboprobe T7/SP6 kit from Promega (Madison, WI)
and the pGEM FL2 plasmid was provided by Dr. Dong Sung An
at University of California, Los Angeles. The detection limit of the
assay was 20,000 HIV-1 copies/ml mouse plasma.
Sequencing analysis
Viral RNA was extracted from mouse plasma using QIAamp
Viral RNA Mini Kit from Qiagen (Valencia, CA). The RNA
(500 ng) was reverse transcribed and amplified using the
SuperScript III One-Step RT-PCR System with Platinum Taq
High Fidelity from Invitrogen (Carlsbad, CA). The primer
sequences were: JR-CSF env forward primer, 59-GGC AAT
GAG AGT GAA GGG GAT CAG-39; JR-CSF env reversed
primer, 59-CAT CTT ATA GCA AAG CCC TTT CCA AGC C-
39. The primers flanked the whole 2.5-kb envelope gene. The PCR
product was then gel-purified and cloned into the TOPO vector
using the TOPO XL PCR Cloning Kit from Invitrogen (Carlsbad,
CA). More than 10 clones were picked for each RNA sample. The
plasmids were then extracted and sent to sequencing at Laragen
(Los Angeles, CA) or Sequetech (Mountain View, CA). The
sequencing primer was 59-GTC AGC ACA GTA CAA TGT
ACA CAT GGA ATT AG -39 and annealed upstream of the Asn
residues that linked 2G12 epitope-containing carbohydrate chains
[7]. Mutations at N295, N332, N339, N386, N392, N448 and
adjacent Ser/Thr residues were then analyzed.
In vitro neutralization assay
We used a previously described pseudovirus neutralization
assay, which measures the reduction in luciferase reporter gene
expression in the presence of 2G12 monomer or dimer following a
single round of pseudovirus infection in TZM-bl cells [20].
Pseudoviruses were generated by cotransfection of 293T cells with
an envelope expression plasmid and a replication-defective
backbone plasmid. (For envelope expression, viral RNA was
extracted from mouse plasma 4 weeks after HIV-1 challenge and
reverse transcribed. The complete envelope gene was amplified
from viral cDNA and the PCR product was then gel-purified and
cloned into the pcDNA3 vector.) Each 2G12 protein was tested in
triplicate with a 3-fold dilution series, and incubated with the
pseudoviruses (250 infectious viral units per well) for 1 h at 37uC.
After the incubation, 10,000 TZM-bl cells were added to each
well, followed by incubation for 2 days. Cells were then lysed and
assayed for luciferase expression by using Bright-Glo (Promega;
Madison, WI) and a Victor3 luminometer (Perkin-Elmer;
Waltham, MA).
Supporting Information
Figure S1 Rag22/2cc
2/2 mice were intrahepatically (i.h.)
injected with 0.1,0.26106 human CD34+ hematopoietic stem
and progenitor cells at 1 day of age to become humanized mice.
(A) Mice were screened for the percentages of human CD45+ cells
in the peripheral blood at 6 weeks of age and those with good
reconstitution (.20% CD45+ cells) were chosen for the study. The
reconstitution rates were not different among the groups. (B)
Humanized mice were injected intravenously (i.v.) with 0.5 mg of
purified 2G12 monomer (n = 6) or 2G12 dimer (n = 5) at 4 months
of age and challenged by the JR-CSF strain of HIV-1 (i.v.; 400 ng
of p24) one day after the passive transfer. After the mice were
sacrificed, mesenteric lymph nodes (mLN) were harvested, fixed,
and sectioned for immunohistochemical analysis of CD4 and CD8
expression. The numbers of CD4+ and CD8+ cells were counted
manually and the ratios of CD4:CD8 are shown. (C) After the
mice were sacrificed, CD4 and CD8 T cell populations in the
thymus were measured by flow cytometry. The percentages of
CD4+CD82 cells in CD45+ human thymocytes were plotted.
Found at: doi:10.1371/journal.ppat.1001225.s001 (0.44 MB TIF)
Figure S2 Rag22/2cc
2/2 mice were intrahepatically (i.h.)
injected with 0.1,0.26106 human CD34+ hematopoietic stem
and progenitor cells at 1 day of age. When the mice were 3-month-
old, we delivered 2G12 through subcutaneous (s.c.) injection of a
cell line on the back of the mice. The cell line, 293T/TK/2G12,
formed controllable backpacks on the mice (see the text and
Materials and Methods for details). The backpack size was closely
monitored biweekly and the prodrug ganciclovir was injected (i.p.)
after HIV challenge and when the backpacks exceeded the size
limit of 1.5 cm2. The concentrations of 2G12 (monomer plus
dimer) produced in the blood were monitored by ELISA. (A)
Analysis of the backpack size versus the plasma level of 2G12
showed significant correlation (R2 = 0.53, p,0.0001) between the
two. Seventy-one data points from weeks 2–7 after 293T/TK/
2G12 injection were plotted on the graph. Earlier data points were
excluded because the backpacks were not detectable at the time.
(B) The backpacks expressing wild-type 2G12 were named 2G12
backpacks (‘‘2G12 BP’’; n = 8) whereas the ones expressing the D2
mutant were named D2 backpacks (‘‘D2 BP’’; n = 7). Another
group of mice were made to carry wild-type 2G12-expressing
backpacks (‘‘BP ’’; n = 7) till the plasma concentrations of 2G12
(monomer plus dimer) reached 100 mg/ml before HIV inocula-
tion. Viral RNA was extracted from mouse plasma after HIV
infection and the viral load was measured. Area under the curve
(AUC) of the 4 groups from week 0 to week 4 was calculated and
plotted. Both ‘‘D2 BP’’ and ‘‘BP ’’ groups had significantly lower
viral load than the ‘‘HIV; No Ab’’ control (p,0.01). (C) After the
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mice were sacrificed, the spleens were harvested, fixed, and
sectioned for immunohistochemical analysis of HIV-1 p24. The
numbers of p24+ cells were counted manually and presented as the
number of cells per mm2 area of the specimen.
Found at: doi:10.1371/journal.ppat.1001225.s002 (0.37 MB TIF)
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